RT Journal Article
SR Electronic
T1 Cutaneous and acral melanoma cross-OMICs reveals prognostic cancer drivers associated with pathobiology and ultraviolet exposure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.30.22275777
DO 10.1101/2022.05.30.22275777
A1 Vicente, Anna Luiza Silva Almeida
A1 Novoloaca, Alexei
A1 Cahais, Vincent
A1 Awada, Zainab
A1 Cuenin, Cyrille
A1 Spitz, Natália
A1 Carvalho, André Lopes
A1 Evangelista, Adriane Feijó
A1 Crovador, Camila Souza
A1 Reis, Rui Manuel
A1 Herceg, Zdenko
A1 de Lima Vazquez, Vinicius
A1 Ghantous, Akram
YR 2022
UL http://medrxiv.org/content/early/2022/05/31/2022.05.30.22275777.abstract
AB Ultraviolet radiation (UV) is causally linked to cutaneous melanoma, yet the underlying epigenetic mechanisms, known as molecular sensors of exposure, have never been characterized in clinical biospecimen. Here, we integrate clinical and epigenome (DNA methylome), genome and transcriptome profiling of 112 cutaneous melanoma from two multi-ethnic cohorts. We identify UV-related alterations in regulatory regions and immunological pathways, with multi-OMICs cancer driver potential affecting patient survival. TAPBP, the top gene, is critically involved in immune function and encompasses several UV-altered methylation sites that were validated by targeted sequencing, providing cost-effective opportunities for clinical application. The DNA methylome also reveals non UV-related aberrations underlying pathological differences between the cutaneous and 17 acral melanomas. Unsupervised epigenomic mapping demonstrated that non UV-mutant cutaneous melanoma more closely resembles acral rather than UV-exposed cutaneous melanoma, with the latter showing better patient prognosis than the other two forms. These gene-environment interactions reveal translationally impactful mechanisms in melanomagenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe thank all melanoma patients who contributed to the study. This work was supported by Public Ministry of Labor, Campinas (Research, Prevention, and Education of Occupational Cancer), Barretos Cancer Hospital and International Agency for Research on Cancer. A.L.S.A.V. was supported by FAPESP (grant no 2016/15941-3 and 2017/09612-0). We thank the BCH biobank for DNA isolation and sample processing and storage. The initial development of the multi-OMICs driver score was partially supported by the grant from the Institut National du Cancer (INCa, France), La direction generale de loffre de soins (DGOS), and INSERM (SIRIC LYriCAN, INCa-DGOS-Inserm_12563) to Z.H.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the Brazilian national and institutional ethical policies, and it was previously approved by the Barretos Cancer Hospital Ethics Committee (716/2013).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe 450K data generated in this study have been deposited in the GEO database under accession code GSE202750 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE202750]. The WGS data are available in the ICGC database [https://dcc.icgc.org/projects/SKCA-BR]. The 450K, RNAseq and WES data on melanoma samples from TCGA were downloaded from the GDC Legacy Portal [https://portal.gdc.cancer.gov/legacy-archive/search/f] and cBioPortal [https://www.cbioportal.org/datasets]. https://drive.google.com/drive/folders/1LG4HbM6aeRL4TME0aykcUshDKGSHIbPT?usp=sharing